SCHEMBL24468604

SCHEMBL24468604

Nc1nc2cc(Cl)c(C(=O)O)cc2c2c1COC2

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.35
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA3 P07451 1/20 0.34
CA4 P22748 1/20 0.34
CA6 P23280 1/20 0.34
CA5A P35218 1/20 0.34
CA7 P43166 1/20 0.34
CA9 Q16790 1/20 0.34
CA13 Q8N1Q1 1/20 0.34
CISD1 Q9NZ45 1/20 0.34
CA14 Q9ULX7 1/20 0.34
CA5B Q9Y2D0 1/20 0.34
TBK1 Q9UHD2 7/20 0.33
IKBKE Q14164 4/20 0.33
POLB P06746 3/20 0.33
ACHE P22303 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29650879 1.00 KDM4E (0.35) KDM4ECA12CA1CA2CA3
Hydrochloric Acid SCHEMBL26918508 0.88 ACHE (0.32) KDM4EACHE
SCHEMBL31515392 0.85 ACHE (0.44) KDM4EACHEMEN1KMT2ATSHR
SCHEMBL31515361 0.85 ACHE (0.44) KDM4EACHEMEN1KMT2ATSHR
SCHEMBL29650675 0.84 TBK1 (0.37) KDM4ETBK1IKBKEALDH1A1
SCHEMBL24468460 0.84 KDM4E (0.40) KDM4ETBK1IKBKEPOLBACHE
SCHEMBL24468115 0.84 TBK1 (0.37) KDM4ETBK1IKBKEALDH1A1
SCHEMBL26918045 0.82 ACHE (0.47) KDM4ECA12CA1CA2CA9
SCHEMBL24468456 0.81 KDM4E (0.42) KDM4EACHEMEN1KMT2ATSHR
SCHEMBL24468333 0.81 ASPH (0.37) KDM4ETBK1IKBKEALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117062816-A Tricyclic-amide-bicyclic PRMT5 inhibitors 美国安进公司 2023-11-14 CN disclosed
US-20220194955-A1 NOVEL PRMT5 INHIBITORS AMGEN INC. (US) 2022-06-23 US disclosed
WO-2022132914-A1 PRMTS INHIBITORS AMGEN INC. (US) 2022-06-23 WO disclosed
WO-2022115377-A1 TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS AMGEN INC. (US) 2022-06-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220194955-A1 NOVEL PRMT5 INHIBITORS PRMT5, PRMT1, PRMT6 KDM4E 36/4885CA12 4823/4885CA1 4757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.